Are we focused on the wrong risk type in genetic screening?

Breast cancer screening study shows new paths to population screening

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A common perception of genetic screening is that only individuals at high risk of certain diseases will be identified. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Cassie Hajek, MD
Medical director, Helix
Table of Contents

YOU MAY BE INTERESTED IN

For decades, we have faced a central challenge in colorectal cancer screening. One in three eligible Americans—over 50 million people—remain unscreened despite established methods like colonoscopy or stool-based tests existing for decades. This gap persists even though early detection saves lives, and even as colorectal cancer is now the number one cancer killer for Americans under 50.
Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment. 
Cassie Hajek, MD
Medical director, Helix

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login